Charles Schwab’s Beta Bionics BBNX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$7.5M Buy
395,182
+44,309
+13% +$796K ﹤0.01% 2315
2026
Q2
$5.5M Buy
350,873
+28,406
+9% +$338K ﹤0.01% 2430
2026
Q1
$3.23M Sell
322,467
-9,156
-3% -$135K ﹤0.01% 2577
2025
Q4
$10.1M Buy
331,623
+931
+0.3% +$24.9K ﹤0.01% 2138
2025
Q3
$6.57M Buy
330,692
+228,467
+223% +$4.01M ﹤0.01% 2308
2025
Q2
$1.49M Buy
102,225
+611
+0.6% +$8.65K ﹤0.01% 2765
2025
Q1
$1.24M Buy
+101,614
New +$1.89M ﹤0.01% 2769

Other funds holding BBNX

Charles Schwab's BBNX Position: Q3 2026 in Review

Charles Schwab increased its Beta Bionics (BBNX) stake by 13% in Q3 2026, buying an estimated $796K and bringing the position to 395,182 shares worth $7.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2315.

Charles Schwab first reported a position in BBNX in Q1 2025 and has held it in 7 quarters since. The position peaked at $10.1M in Q4 2025. 153 funds tracked by Wall St. Rank hold BBNX as of Q3 2026.

  • Charles Schwab held 395,182 shares of Beta Bionics worth $7.5M as of Q3 2026.
  • Charles Schwab bought 44,309 Beta Bionics shares in Q3 2026, an estimated $796K.
  • Beta Bionics made up ﹤0.01% of Charles Schwab's portfolio in Q3 2026, its #2315 holding.
  • Charles Schwab first reported a position in Beta Bionics in Q1 2025 and has held it in 7 quarters since.
  • Charles Schwab's Beta Bionics position peaked at $10.1M in Q4 2025.
  • 153 funds tracked by Wall St. Rank held Beta Bionics as of Q3 2026.

Based on Charles Schwab's 13F filing for Q3 2026, filed 16 Nov 2026.